Biosensor developer Biolinq said today it closed a $10 million Series A financing round to support its wirelessly-enabled biosensor patch designed for continuous monitoring of biomarkers, with an initial focus on monitoring glucose in diabetes patients.
The round was led by M Ventures in collaboration with Hikma Ventures and joined by Grey Sky Venture Partners, Three Leaf Ventures, LifeSci Venture Partners and individual donators, the San Diego, Calif.-based company said.
Read the whole story on our sister site, Drug Delivery Business